AxoGen (AXGN) Corporate presentation summary

Mission and market opportunity

• Focus on restoring health and quality of life by making peripheral nerve repair a standard of care.

• Targets a $5.6B US nerve care market with over 1.5 million annual injuries in key segments: extremities, breast reconstruction, oral/maxillofacial, and prostate surgery.

• Nerve injuries significantly impact patient quality of life, with high incidence rates in trauma, surgery, and amputation.

Product portfolio and innovation

• Avance is the first FDA-approved biologic for nerve discontinuity repair, preserving native nerve structure and supporting regeneration.

• Comprehensive portfolio includes Avance, Axoguard, and Avive+ products, covering connection, protection, and termination in nerve repair.

• Ongoing innovation with new product development and clinical applications, including prostate and breast neurotization.

Market development and education

• Key barriers include lack of standardized care guidelines, low awareness, inefficient referral pathways, and incomplete insurance coverage.

• Strategic plan prioritizes commercial expansion, clinical evidence generation, and innovation to drive growth and standard of care adoption.

• Extensive education and training initiatives, with 75% of hand fellows and over 1,400 surgeons trained on nerve repair algorithms.